Target intelligence / Profile preview

Inward-rectifier potassium channel subfamily 2 (Kir2.x)

Target
Kir2.x
Molecular classification
Ion channel, Potassium channel, Inward-rectifier potassium channel
01

Overview

The inward-rectifier potassium channel subfamily 2 (Kir2.x) consists of four members (Kir2.1–Kir2.4) that are crucial for maintaining the resting membrane potential and controlling the excitability of neurons, cardiomyocytes, and skeletal muscle cells (Hibino et al., 2010, Physiological Reviews). These channels are characterized by their ability to conduct potassium ions more readily into the cell than out of it, a property known as inward rectification, which is mediated by the voltage-dependent block of the pore by intracellular polyamines and magnesium ions (UniProt P60584). In the heart, Kir2.1 is the primary conductor of the inward rectifier current (IK1), which is vital for the final phase of repolarization and the stability of the resting potential (De Boer et al., 2010, Cardiovascular Research). Dysregulation or genetic mutations in Kir2.x channels are associated with several clinical conditions, including Andersen-Tawil syndrome, Short QT syndrome, and various forms of atrial and ventricular arrhythmias (StatPearls, Andersen-Tawil Syndrome). Consequently, Kir2.x channels are significant therapeutic targets for antiarrhythmic drugs, although achieving isoform selectivity remains a major challenge in drug development (PubMed: 20634230).

Other names
Kir2IRKStrong inward rectifier potassium channelKCNJ subfamily 2IK1 channel
02

Mechanism of action

Blockade of the ion-conducting pore to inhibit the outward flow of potassium ions during the late phase of the action potential, thereby modulating membrane excitability.

03

Biological functions

Maintenance of resting membrane potentialCardiac repolarizationRegulation of cell excitabilityPotassium homeostasis
04

Disease associations

Andersen-Tawil syndromeShort QT syndrome type 3Atrial fibrillationPeriodic paralysisVentricular arrhythmia
05

Safety considerations

Pro-arrhythmic riskQT interval prolongationSkeletal muscle weaknessPotential for drug-induced periodic paralysis
06

Interacting drugs

Chloroquine

6 more in the full profile.

07

Biomarkers

KCNJ2 gene mutationsQT interval durationU-wave presence on ECGSerum potassium levels

Beyond the preview

Go deeper on Inward-rectifier potassium channel subfamily 2 (Kir2.x).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inward-rectifier potassium channel subfamily 2 (Kir2.x).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call